CRESEMBA Y ZAVICEFTA

1. Since 1980, the number of antibiotics being approved has ______________ while the use of carbapenem antibiotics has ______________ .

• Increased; increased
• Increased; decreased
• Decreased; increased
• Decreased; decreased

2. What is the mechanism of action for each of the active ingredients in ZAVICEFTA?

• Ceftazidime inhibits bacterial peptidoglycan cell wall synthesis, leading to bacterial cell lysis and death; avibactam inhibits β-llactamases, preventing the hydrolysis of ceftazidime so that it may remain active
• Ceftazidime inhibits β-llactamases, preventing the hydrolysis of avibactam so that it may remain active; avibactam inhibits bacterial peptidoglycan cell wall synthesis, leading to bacterial cell lysis and death
• Ceftazidime inhibits bacterial protein synthesis, leading to bacterial cell lysis and death; avibactam inhibits β-llactamases, preventing the hydrolysis of ceftazidime so that it may remain active
• Ceftazidime inhibits β-lactamases, preventing the hydrolysis of avibactam so that it may remain active; avibactam inhibits bacterial protein synthesis, leading to bacterial cell lysis and death

3. Which of the following drugs has been shown to be antagonistic toward ZAVICEFTA in vitro?

• Probenecid
• Levofloxacin
• Chloramphenicol
• Vancomycin

4. In RECLAIM 1 and RECLAIM 2, which of the following agents was used as the control?

• Meropenem
• Metronidazole
• Doripenem
• Aztreonam

5. In RECAPTURE 1 and 2, what percentage of patients in the mMITT population achieved a perpatient microbiological response at TOC for each treatment group?

• 71.2% of the ceftazidime/avibactam group and 54.5% of the doripenem group
• 77.4% of the ceftazidime/avibactam group and 71.0% of the doripenem group
• 84.5% of the ceftazidime/avibactam group and 86.3% of the doripenem group
• 91.7% of the ceftazidime/avibactam group and 92.5% of the doripenem group